Tube Racks
Abcam Pirfenidone, orally active anti-inflammatory antifibrotic agent, 50MG
MW 185.22 Da, Purity >99%. Orally active anti-inflammatory, antifibrotic and antiproliferative agent. Blood-brain barrier permeable. Shown to modulate cytokines TGF-β and TNF-α.
The product is subject to the following: Abcam Restricted Use Statement
Abcam JP1302 dihydrochloride, alpha2C antagonist, 10MG
MW 441.4 g/mol, Purity >99%. Potent and highly selective α₂C antagonist (Kb values for human subtypes are 28 (α₂C), 1470 (α₂B), 1700 (α₂D) and 3150 nM (α₂A)). Shows antidepressant and antipsychotic effects. Active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Withaferin A from Withania somnifera, 1MG
MW 470.6 g/mol, Purity >98%. Naturally occurring withanolide/steroidal lactone with anticancer properties. Demonstrates a number of cellular effects including the covalent binding to annexin II, inhibition of chymotrypsin-like activity, PKC and caspase 3. Causes translocation of cyctochrome C to the nucleous and the cleavage of PLC-γ1. Down-regulates Notch 1, 3, cdc25C, phosphorylated Akt and bcl-2 proteins.
The product is subject to the following: Abcam Restricted Use Statement
Abcam VU0119498, M1 muscarinic receptor agonist and pan mAChR M3, M5 PAM, 10MG
MW 316.15 Da, Purity >99%. M1 muscarinic receptor agonist (EC50 = 3.1 μM) and pan mAChR M3, M5 positive allosteric modulator (PAM). Neuroprotective agent. Active *in vitro*.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Phentolamine hydrochloride, Non-selective alpha antagonist, 500MG
MW 317.8 Da, Purity >98%. Potent, reversible, non-selective α antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam DNQ x , AMPA / kainate antagonist, 100MG
MW 252.14 Da, Purity >99%. AMPA / kainate antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam (S)-(+)-Rolipram, PDE4 inhibitor, 10MG
MW 275.34 Da, Purity >99%. PDE4 inhibitor (IC₅₀ = 0.58 μM). Less active enantiomer. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam MMPIP, mGlu7 allosteric antagonist, 1MG
MW 333.3 Da, Purity >98%. Potent, selective allosteric antagonist at mGlu7 receptors. Inhibits agonist-induced intracellular calcium mobilisation and cAMP accumulation (IC50 values are 26 and 610 nM). Also displays intrinsic activity; increasing forskolin-induced cAMP accumulation in the absence of an agonist. Exhibits no significant activity at mGluR1, mGluR2, mGluR3, mGluR4, mGluR5, and mGluR8. Also available in Kit: mGlu antagonists (ab120322).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Lariatin A, antimycobacterial agent, 250UG
MW 2036.3 Da, Purity >95%. Potent antimycobacterial agent. Contains a lasso structure. Lariatin B analog. Inhibits the growth of Mycobacterium smegmatis (MIC = 3 μM) and Mycobacterium tuberculosis (MIC = 0.2 μM). Shows antimycobacterial effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam MTEP, mGluR5 antagonist, 5MG
MW 200.26 Da, Purity >99%. Potent and selective mGluR5 antagonist. Acts as a negative allosteric modulator at mGluR5. Shows 5-fold more potent anxiolytic effects than MPEP (ab120008). Shows antidepressant and neuroprotective effects in vivo. Orally active. Blood-brain barrier permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CAY10572 (PHA-767491), Cdc7 and Cdk9 kinase inhibitor, 50MG
MW 249.69 Da, Purity >98%. Potent Cdc7 and Cdk9 kinase inhibitor (IC₅₀ values are 10 and 34 nM for Cdc7 in the presence of 1.5 μM ATP and Cdk9 respectively). Induces apoptosis in cancer cell lines. Shows synergistic antitumor effects in vivo with 5-fluorouracil (ab142387).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Epicatechin, Flavonoid, 1MG
MW 290.27 Da, Purity >99%. Flavonoid. Displays multiple biological effects including antioxidant, antinociceptive, cardioprotective, anti-inflammatory and antineoplastic effects.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Temsirolimus (CCI779), mTORC1 comple x inhibitor, 10MG
MW 1030.3 Da, Purity >98%. Selective mTORC1 complex inhibitor (IC50 = 1.76 µM). Water-soluble rapamycin (ab120224) pro-drug. Rapidly converts to rapamycin *in vivo*. Inhibits proliferation and angiogenesis and induces apoptosis and autophagy *in vivo*.
The product is subject to the following: Abcam Restricted Use Statement
Abcam DBeQ, p97 ATPase inhibitor, 10MG
MW 340.4 Da, Purity >99%. Selective, potent, reversible and ATP-competitive p97 ATPase inhibitor (IC₅₀ = 1.5 μM). Inhibits a number of cellular processes including ER-associated degradation, ubiquitin fusion degradation and autophagosome maturation. Decreases cancer cell growth and induces activation of caspases 3 and 7.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TMPyP4 tosylate, Telomerase inhibitor, 50MG
MW 1363.6 g/mol, Purity >94%. Cationic porphyrin. Telomerase inhibitor (IC₅₀ = 6.5 μM). Binds and stabilizes DNA G quadruplexes resulting in telomerase inhibition. Displays antitumor effect.
The product is subject to the following: Abcam Restricted Use Statement